"uuid:ID","label","rationale","name","description","id","instanceType"
"28c237b1-e777-4b4d-84de-86b96461938d","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study","StudyDesign_1","StudyDesign"
